Several randomized controlled trials (RCTs) evaluated the afatinib efficacy in patients with advanced non-small cell lung cancer (NSCLC) and recurrent/metastatic head neck squamous carcinoma (R/M HNSCC). This review systemically outlined meta-analyzed NSCLC R/M HNSCC terms of overall survival (OS) progression-free (PFS) endpoints. Records were retrieved from PubMed, Web Science, ScienceDirect 2...

background: to determine which radiotherapy parameters are associated with the tumor response of locally advanced non-small cell lung cancer (nsclc) patients undergoing concurrent chemoradiotherapy. materials and methods: thirty one patients with iiia/iiib nsclc underwent chemoradiotherapy with a median dose of 63 gy. on our actual treatments, we made radiotherapy planning to cover the planning...

Inflammatory cytokines and oxidative stress are two critical mediators in inflammation-associated cancer. Interleukin-6 (IL-6) is one of the most critical tumor-promoting cytokines in non-small cell lung cancer (NSCLC). In our recent study, we confirmed that NADPH oxidase 4 (NOX4), an important source of reactive oxygen species (ROS) production in NSCLC cells, promotes malignant progression of ...

Lung cancer is the most common cause of cancer-related deaths worldwide, as 2.1 million people were diagnosed with disease and 1.8 passed away from lung worldwide in 2018.[1] The condition split into two sections: Small Cell Cancer (SCLC) Non-Small (NSCLC). In this research paper, I discuss key aspects NSCLC, including risk factors, symptoms, diagnosis, treatment, prevention, epidemiology. Last...

PURPOSE Targeted therapy increases survival and the quality of life of non-small cell lung cancer (NSCLC) patients but it needs precise histological subtyping. The present study evaluated 6 monoclonal antibodies for the differential diagnosis of NSCLC on small-sized tissue samples. METHODS 50 small-sized tissue samples were obtained by bronchoscopy or fine needle aspiration biopsy (FNAB). Acc...

The expression level and clinical significance of NR4A1 are presently unknown in the non-small-cell lung carcinoma (NSCLC). This study aimed to explore the expression, prognostic value, and function of NR4A1 in NSCLC. METHODS Clinicopathological parameters of 167 NSCLC patients who received radical surgery from January 2007 and December 2012 were retrospectively reviewed. The NR4A1 expression...

Background & Objective:  Matrix metalloproteinases-9 (MMP-9) is one of the most important enzymes to breakdown extracellular matrix which plays a major role in tumor invasion and metastasis. This study aimed to determine tumor MMP-9 expression in non-small-cell lung carcinoma (NSCLC) and whethe...

Idiopathic interstitial pneumonia (IIP) is considered to be one of the risk factors for lung cancer (LC). However, therapeutic options for patients with LC complicated by IIP are not well established. In this study, we investigated the feasibility and efficacy of chemotherapy for patients with non-small cell lung cancer (NSCLC) complicated by IIP (NSCLC-IIP). We retrospectively analyzed 22 NSCL...

Ferroptosis therapy gradually becomes a new strategy for the treatment of non-small cell lung cancer (NSCLC) because its active iron metabolism. Because hypoxic microenvironment in NSCLC inhibits ferroptosis heavily,...

miR-3940-5p level was lower in non-small cell lung cancer (NSCLC) tumor tissues than that in the matched tumor-adjacent tissues and correlated with clinicopathological features. Cyclin D1 (CCND1), a key driver of malignant transformation in NSCLC, was overexpressed in many cancers, including NSCLC. The ubiquitin specific peptidase-28 (USP28) was also overexpressed in NSCLC and associated with p...